| Identification | Back Directory | [Name]
(S)-1,2,3,4-tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methylisoquinolin-7-ol | [CAS]
485-19-8 | [Synonyms]
reticuline
(S)-Reticuline
Reticuline (>90% ee)
(1S)-1-[(3-hydroxy-4-methoxy-phenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol
(S)-1,2,3,4-tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methylisoquinolin-7-ol
2-Methoxy-5-[[(1S)-2-methyl-6-methoxy-7-hydroxy-1,2,3,4-tetrahydroisoquinoline]-1-ylmethyl]phenol
7-Isoquinolinol, 1,2,3,4-tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-, (1S)-
[1S,(+)]-1,2,3,4-Tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methylisoquinolin-7-ol
[1S,(+)]-1,2,3,4-Tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methylisoquinoline-7-ol | [EINECS(EC#)]
207-611-3 | [Molecular Formula]
C19H23NO4 | [MOL File]
485-19-8.mol | [Molecular Weight]
329.39 |
| Chemical Properties | Back Directory | [Melting point ]
125-126°C | [Boiling point ]
648.96°C (rough estimate) | [density ]
1.4371 (rough estimate) | [refractive index ]
1.6800 (estimate) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
9.95±0.10(Predicted) | [color ]
Off-white to yellow | [Optical Rotation]
+88.318 (c 0.21, ethanol) | [InChI]
InChI=1S/C19H23NO4/c1-20-7-6-13-10-19(24-3)17(22)11-14(13)15(20)8-12-4-5-18(23-2)16(21)9-12/h4-5,9-11,15,21-22H,6-8H2,1-3H3/t15-/m0/s1 | [InChIKey]
BHLYRWXGMIUIHG-HNNXBMFYSA-N | [SMILES]
[C@H]1(CC2=CC=C(OC)C(O)=C2)C2=C(C=C(OC)C(O)=C2)CCN1C |
| Hazard Information | Back Directory | [Chemical Properties]
Pale Yellow Solid | [Uses]
Precursor of many aporphine and morphine-type alkaloids. | [Definition]
ChEBI: The (S)-enantiomer of reticuline. | [in vivo]
Reticuline (5, 10 and 20 mg/kg, i. v., randomly) injections produced an intense hypotension in normotensive rats. The hypotensive effect of Reticuline is probably due to a peripheral vasodilation in consequence of: 1) muscarinic stimulation and NOS activation in the vascular endothelium, 2) voltage-dependent Ca2+ channel blockade and/or 3) inhibition of Ca2+ release from norepinephrine-sensitive intracellular stores[2]. | [IC 50]
JAK2; STAT3; NF-κB; Human Endogenous Metabolite | [storage]
Store at -20°C |
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
|